Skip to main content

Month: June 2023

Aurimas Likus Heads the Finance Department of Utenos Trikotažas

June 27, 2023 Utenos Trikotažas appoints Aurimas Likus as its new Head of Finance, replacing Živilė Jonaitytė, who held the position for over three years. With over 15 years of experience in corporate finance and banking, Aurimas assumes this role while continuing his position as the Financial Control Lead at the SBA Group, the primary shareholder of Utenos Trikotažas. Before joining the SBA Group, A. Likus spent a significant part of his career working at SEB Bank, where he held the position of Client Executive in Corporate banking. During this time, he played a pivotal role in managing large corporate client financing projects, navigating complex financial transactions such as mergers and acquisitions, and providing business advisory services. “I am confident that with Aurimas’ leadership, we will capitalize on our potential...

Continue reading

24/2023 Green Hydrogen Systems – Minimum gross proceeds of DKK 225 million subscribed and rights issue expected to be completed

Company announcement 24/2023 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT IS AN INDICATION OF AN EXPECTATION ONLY AND SHOULD NOT BE INTERPRETED OR CONSTRUED AS A STATEMENT ON THE ACTUAL RESULT OF THE OFFER NOR A CONFIRMATION THAT IT WILL BE COMPLETED. SEE THE DISCLAIMER BELOW. Minimum gross proceeds of DKK 225 million subscribed and rights issue expected to be completed Kolding, Denmark, 27 June 2023 – Green Hydrogen Systems A/S (“Green Hydrogen Systems” or the “Company”) today announces subscription for the minimum gross proceeds of DKK 225 million and that it is expected that the rights issue announced by...

Continue reading

CORRECTION: Notification on the total number of voting rights granted by shares of AUGA group, AB and capital

Correction: Total number of shares, authorised capital of shares and total number of votes data have been corrected. The correction was made in both languages. Other published data remained unchanged. On 28 April 2023 during the Annual General Meeting of AUGA group, AB (hereinafter – “the Company“)  Shareholders, decision to increase Company’s authorised capital was taken. Security information after the increase of the share capital is as follows:Share type Ordinary registered sharesISIN LT0000127466Nominal, EUR 0.29Total number of shares 231,735,132Authorised capital of the Company, EUR 67,203,188.28Total number of votes 231,735,132Contacts: Mindaugas Ambrasas, AUGA group, AB CFO Phone: +370 620 67296 Email: m.ambrasas@auga.lt

Continue reading

CORRECTION: New wording of AUGA group, AB Articles of Association and the increase of the authorized share capital registered

Correction: the amount of the increased authorized share capital of AUGA group, AB and the number of new ordinary registered shares issued data have been corrected. The correction was made in both languages. Other published data remained unchanged. On 23 June 2023, a new wording of the Articles of Association of AUGA group, AB (hereinafter – “the Company“) was registered in the Register of Legal Entities. The new wording of the Articles of Association was approved on 28 April 2023 during the Annual General Meeting of Company’s Shareholders together with the decision to increase the authorised share capital of the Company by EUR 586,098,70 issuing 2,021,030  new ordinary registered shares. The right to subscribe and acquire new shares granted to the employees and/or members of the corporate bodies of the Company or its subsidiaries...

Continue reading

Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023

RDT platform offers unique approach for tailored delivery of radioactive payloads to solid tumors RDT platform is focused on improving both tumor-targeting efficiency and safety over historic protein-based radioligand approaches ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 27, 2023 (GLOBE NEWSWIRE) — Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, has announced it will present on its Radio DARPin Therapy (RDT) Platform at the 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting being held from June 24-27 in Chicago, Illinois. The presentation details are as follows: Title: DARPin platform for the development of powerful targeting agents for radioligand therapySession Title: Innovative...

Continue reading

SIKA CONTINUES TO EXPAND PRODUCTION IN GROWTH MARKET INDIA

SIKA CONTINUES TO EXPAND PRODUCTION IN GROWTH MARKET INDIA Sika is opening a new plant in Kharagpur, eastern India, and continues to expand production capacity in the fast-growing Indian market. The plant will manufacture mortar products, concrete admixtures, and shotcrete accelerators for customers in the West Bengal region, which has more than 100 million inhabitants. By ramping up production capacity at its new site, Sika is expanding its supply capacity in eastern India. Alongside state-of-the-art manufacturing lines, the new factory offers office space, laboratories, and warehousing and logistics. The factory is located in an industrial park that profits from an ideal infrastructure. Overall, Sika has now twelve manufacturing facilities in India and has been active in the Indian market for close to four decades. Mike Campion, Regional...

Continue reading

Kinarus Therapeutics signed subordinated bridge loans to ensure further liquidity

Basel, Switzerland, June 26, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, today announced the signing of subordinated bridge loan agreements with existing shareholders to ensure further liquidity is available to Kinarus during the period of time required for bridging the pending transfer of funds pursuant to a CHF1.5 million convertible loan investment from ChaoDian (Hangzhou) Investment Management Co (CDIM), in Kinarus. The bridge loans are immediately available and Kinarus can decide when to request delivery of funds, , depending on the settlement of the funds to be transfer from CDIM. Dr Hari Kumar, Chairman of the Board of Kinarus Therapeutics Holding AG, commented: “While CDIM’s commitment...

Continue reading

Adevinta appoints Elisabeth Peyraube as Chief Financial Officer

Oslo, 27 June 2023 – Adevinta ASA (ADE) today announced the appointment of Elisabeth Peyraube as Chief Financial Officer (CFO), effective September 2023. Elisabeth is currently CFO and deputy CEO at video media company Brut. Prior to that, Elisabeth was the CFO and Chief Operating Officer, EMEA & APAC, at Match Group, the owner of a broad portfolio of dating apps. She will succeed Uvashni Raman, who in February 2023 announced her intention to step down. “Elisabeth is a proven leader with a breadth of relevant experience, having held Group, divisional and regional CFO roles across international businesses of varying scale, geographic presence and ownership structure,” commented Antoine Jouteau, CEO, Adevinta. “She brings with her strong digital consumer and media platform credentials, combined with extensive experience leading...

Continue reading

ForFarmers N.V.: ForFarmers cancels nearly 6 million shares on 27 June 2023

Lochem, 27 June 2023 ForFarmers cancels nearly 6 million shares on 27 June 2023 ForFarmers announces the cancellation of 5,935,004 shares on 27 June 2023. ForFarmers has repurchased these shares for a total amount of €23,245,424 under the share-buyback programme to the amount of at maximum €50 million, which was approved by the General Meeting of Shareholders in 2021. On 15 March 2022, ForFarmers announced that it considered it prudent to temporarily suspend the share-buyback programme, which had started on 2 December 2021. Subsequently, ForFarmers reported in its Third quarter 2022 trading update on 1 November, not to restart the share-buyback programme. The current share-buyback program for a maximum of 625,000 shares, for a maximum amount of €3,125,000, is still ongoing. This programme started on 18 April 2023 for the purpose of ForFarmers...

Continue reading

23/2023 Green Hydrogen Systems – Notification of transactions by persons discharging managerial responsibilities

Company announcement 23/2023 Notification of transactions by persons discharging managerial responsibilities in Green Hydrogen Systems A/S Kolding, Denmark, 27 June 2023 – In accordance with article 19 of the Market Abuse Regulation, Green Hydrogen Systems A/S (“Green Hydrogen Systems”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in Green Hydrogen Systems and persons closely associated with them in Green Hydrogen Systems’ shares and other financial instruments linked thereto: 1.Details of the person discharging managerial responsibilities/person closely associateda)NameLars Valsøe Bertelsen2.Reason for the notificationa)Position/statusMember of the Board of Directors in Green Hydrogen Systems A/Sb)Initial notification/amendmentInitial notification3.Details...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.